Why the study?
TAVI is associated with thromboembolic and bleeding complications, necessitating optimal antithrombotic therapy to balance these risks amidst evolving trial evidence and guidelines.
Does single antiplatelet therapy or tailored oral anticoagulation improve thromboembolic and bleeding outcomes compared to dual antiplatelet therapy or routine anticoagulation in patients undergoing TAVI?
Does single antiplatelet therapy or tailored oral anticoagulation improve thromboembolic and bleeding outcomes compared to dual antiplatelet therapy or routine anticoagulation in patients undergoing TAVI?
Answers are grounded in this paper and cite their sources.
This review synthesizes contemporary trial evidence supporting single antiplatelet therapy as the default strategy post-TAVI for patients without an anticoagulation indication, while advising against routine anticoagulation solely to prevent subclinical leaflet thrombosis.
Transcatheter aortic valve implantation (TAVI) has revolutionized the management of severe aortic stenosis, particularly in patients at high surgical risk. However, the procedure is associated with thromboembolic and bleeding complications, necessitating optimal antithrombotic therapy (ATT) to balance these risks. This review explores the evolving landscape of ATT post-TAVI, focusing on single antiplatelet therapy (SAPT) versus dual antiplatelet therapy (DAPT), the role of oral anticoagulation (OAC) in atrial fibrillation (AF) patients, and the safety of direct oral anticoagulants (DOACs). Recent clinical trials, including POPular-TAVI, ARTE, GALILEO, ATLANTIS, ENVISAGE-TAVI AF, ACASA-TAVI, and NOTION-4, have reshaped ATT strategies, supporting SAPT for most patients without another indication for anticoagulation while highlighting the uncertainty surrounding routine anticoagulation for prevention of subclinical leaflet thrombosis. Current guidelines advocate an individualized approach based on thrombotic and bleeding risk profiles. As the field progresses, further research is required to refine ATT strategies for improved patient outcomes.
No takes yet. Share an insight, caveat, or question.
Maryam Ismat (2026) conducted a review in Severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI). Single antiplatelet therapy (SAPT) or individualized oral anticoagulation (DOACs/VKAs) vs. Dual antiplatelet therapy (DAPT) or routine oral anticoagulation without an established indication was evaluated on Thromboembolic events (ischemic stroke, valve thrombosis, systemic embolization), major bleeding, and subclinical leaflet thrombosis (HALT).
Synapse has enriched 10 related papers. Consider them for comparative context: